Jun-Young Park 1,2*, Jun Young Park 1,2*, Yong-Gyu Jeong 2*, Joo-Hwan Park 3, Yeon Ho Park 4, Sang-Hyun Kim 5, Dongwoo Khang 1,2,6,7
1Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, 21999, South Korea.
2Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, 21999, South Korea.
3Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, College of Medicine, Gachon University, Incheon, 21565, South Korea.
4Department of Surgery, Gil Medical Center, College of Medicine, Gachon University, Incheon, 21565, South Korea.
5CMRI, Department of Pharmacology, College of Medicine, Kyungpook National University, Daegu, 41944, South Korea.
6Department of Physiology, College of Medicine, Gachon University, Incheon, 21999, South Korea.
7Ectosome Inc., Incheon, 21 999, South Korea.
*These authors havecontributed equally to this work
CORRESPONDING AUTHORS : Sang-Hyun Kim, Dongwoo Khang
Owing to the intrinsic ability of stem cells to target the tumor environment, stem cell membrane-functionalized nanocarriers can target and load active anticancer drugs. In this study, a strategy that focuses on stem cells that self target pancreatic cancer cells was deveolped. In particular, malignant deep tumors such as pancreatic cancer cells, one of the intractable tumors that currently have no successful clinical strategy, are available for targeting and destruction. By gaining the targeting ability of stem cells against pancreatic tumor cells, stem cell membranes can encapsulate nano polylactide-co-glycolide (PLGA) loaded with doxorubicin to target and reduce deep pancreatic tumor tissues. Considering the lack of known target proteins on pancreatic tumor cells, the suggested platform technology could be utilized for targeting any malignant tumors in which surface target receptors are unavailable. This article is protected by copyright. All rights reserved.